Scholar Rock Holding Corporation

SRRK

$55.94

-0.29%

N/A-$0.16

Healthcare

Biotechnology

NASDAQ

Active Trading

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial ...

Fundamental Analysis of SRRK

Loading analysis...

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-16.90x

Current Ratio7.02

Efficiency

ROE-160.19%

ROA-78.04%

Fundamental Analysis of SRRK

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Key Strengths of SRRK

Industry-leading gross margins
Strong cash flow generation
High R&D investment ratio
Market leadership in AI chips

Risk Factors of SRRK

Premium valuation multiples
Semiconductor cycle exposure
Intense competition
Geographic concentration

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$6.70B

-16.9x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.80

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of SRRK

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of SRRK

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of SRRK

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	7.021	—	—	Flat
Quick Ratio	—	7.021	—	—	Flat
Debt / Equity	—	0.803	—	—	Flat

Valuation of SRRK

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-16.37x	—	—	Flat
P/B	—	28.31x	—	—	Flat

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer